The average 12-month consensus price target from financial analysts covering Neumora Therapeutics sits at approximately $6.67 per share, with individual forecasts spanning from a low estimate around $4.00 up to a high of $14.00. This updated average reflects downward revisions made by several research firms following the discontinuation of its lead depression drug, which were partially offset by projected operational cost savings from restructuring initiatives and continued valuation of its remaining early-stage neuroscience pipeline.